Meridia 15 mg Sibutramine HCL Monohydrate

Meridia® 15 mg (Sibutramine HCl Monohydrate)

• Brand: Bariatrics (Abbott)
• Category: Centrally acting monoamine-reuptake modulator (SNRI) – Research chemical
• Content: 30 capsules · 15 mg sibutramine HCl monohydrate per capsule
• Manufactured in: Europe
• Research Notice: FOR RESEARCH USE ONLY. Not for human or veterinary use.

Product Overview

Meridia® 15 mg contains sibutramine hydrochloride monohydrate, a centrally acting

serotonin–norepinephrine reuptake inhibitor (SNRI) historically indicated for weight management

until its withdrawal following the SCOUT cardiovascular-outcomes trial.

It is now used exclusively as a laboratory/analytical reference compound for studies on

monoamine signaling, appetite regulation, toxicology, and forensic method development.

Sibutramine increases synaptic concentrations of serotonin (5-HT) and

norepinephrine (NE) by blocking their reuptake transporters. Its active metabolites

(M1/M2) are chiefly responsible for appetite-suppression pathways and sympathetic activation.

Key Research Highlights

Monoamine reuptake inhibition:

Blocks SERT and NET (± DAT) 5-HT/NE levels enhanced satiety signaling.

Documented extensively in DrugBank and PubChem entries.

Historical pharmacotherapy:

Originally approved for obesity management; later withdrawn (EU/US, 2010) due to increased risk of

non-fatal MI and stroke in high-risk cardiovascular patients (SCOUT trial – NEJM).

Anti-doping relevance:

Classified under WADA Stimulants (in-competition). Athletes must confirm status via Global DRO.

Laboratory value:

Used in metabolic, toxicological, chromatographic, and receptor-transporter profiling workflows.

Mechanism of Action (Simplified)

Sibutramine is metabolized into two active metabolites (M1 & M2) which:

• Block serotonin (SERT) and norepinephrine (NET) transporters
• Increase synaptic monoamines enhanced satiety and reduced caloric intake
• Produce mild sympathetic activation increased HR/BP in clinical history

This profile supports its use in monoamine and appetite-regulation research models.

Scientific Data Table

Field

Data

Chemical Name

Sibutramine hydrochloride monohydrate

Molecular Formula

C17H29Cl2NO (monohydrate salt, PubChem)

Molecular Weight

~334.3 g/mol (monohydrate)

Synonyms

Meridia; Reductil; Sibutramine HCl; Sibutramine HCl Monohydrate

CAS Number

125494-59-9 (monohydrate); 84485-00-7 (base)

PubChem CID

64765 (monohydrate); 5210 (base)

Pharmacology

SNRI (± DAT) appetite/satiety modulation via monoamine elevation

Doping Status

Stimulants – Prohibited in competition (WADA)

Research Background

• SCOUT Trial (NEJM): Increased non-fatal MI and stroke in high-risk cardiovascular groups regulatory withdrawal.
• Mechanistic relevance: Appetite suppression linked to SERT/NET inhibition and downstream hypothalamic pathways.
• Toxicology interest: Cardiovascular, serotonergic, and sympathomimetic components evaluated in controlled studies.

Documented Risks (Historical Medicinal Use)

• Heart rate and blood pressure
• Increased risk of non-fatal MI and stroke (SCOUT)
• Insomnia, dry mouth, headache, constipation
• Possible serotonin-related interactions (SSRIs/MAOIs)

Compliance & Legal Status

• Regulation: Suspended/withdrawn in EU/US (2010). Not marketed as a medicinal product on this site.
• Research-only: Supplied strictly for laboratory/analytical use.
• Sport: Listed under WADA Stimulants (Prohibited In-Competition).
• Researchers and athletes must verify local regulations and anti-doping rules.

Important Notice

This compound is for laboratory research only.

Not for human consumption, therapeutic use, or veterinary application.

Users are responsible for compliance with local laws, regulations, and safety protocols.